Superior the depletion Performance of CD3+ Cells (Comparison with Company M)
Separation performance was evaluated using samples containing 1×10⁷ human PBMCs, processed with CD3 microbeads from Acro, Company M at recommended dosages. Negative fractions were collected, and 1×10⁶ cells from the flow through fraction were immunostained with CD3 Antibody(FITC-anti human CD3 Antibody) and 7-AAD, followed by flow cytometric analysis. Data indicated that Acro microbeads achieved a final purity of 99.50% (baseline: 43.66%). These findings validate outstanding separation performance, confirming an optimal balance of purity and recovery relative to Company M benchmarks (Routinely tested).